(Q38441413)

3 September 2017

1 reference

title

The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors (English)

1 reference

3 September 2017

Mauro Cives

1

1 reference

3 September 2017

Jonathan Strosberg

series ordinal

2

1 reference

3 September 2017

language of work or name

1 reference

1 May 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

75

1 reference

3 September 2017

issue

8

1 reference

3 September 2017

page(s)

847-858

1 reference

Evolution of the diffuse neuroendocrine system--clear cells and cloudy origins

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Grading the neuroendocrine tumors of the lung: an evidence-based proposal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin analogs for diagnosis and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin and Analogues in the Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Antiproliferative effect of somatostatin and analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin Cell Processes as Pathways for Paracrine Secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Pasireotide (SOM230): development, mechanism of action and potential applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin and analogues in the treatment of VIPoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

GPCR mediated regulation of synaptic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Opportunities in somatostatin research: biological, chemical and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Antitumor effects of somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

sst2 Somatostatin Receptor Mediates Negative Regulation of Insulin Receptor Signaling through the Tyrosine Phosphatase SHP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Selective agonism in somatostatin receptor signaling and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Illuminating somatostatin analog action at neuroendocrine tumor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Neuroendocrine tumours of the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Gastrointestinal endocrine tumours. Glucagonomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Bronchial carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Pulmonary carcinoid tumours: indolent but not benign

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Therapeutic biomarkers in lung neuroendocrine neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Targeting the somatostatin receptor in pituitary and neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0397-7

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

21 January 2018

1 reference

12 December 2020

Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma

1 reference

12 December 2020

Medical treatment of benign insulinoma using octreotide LAR: a case report

1 reference

12 December 2020

The expanding role of somatostatin analogs in the management of neuroendocrine tumors.

1 reference

12 December 2020

Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action

1 reference

12 December 2020

DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours

1 reference

12 December 2020

Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours

1 reference

12 December 2020

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

1 reference

12 December 2020

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

1 reference

12 December 2020

Rapid reversal of carcinoid crisis with a somatostatin analogue

1 reference

12 December 2020

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects

1 reference

12 December 2020

Role of somatostatin analogues in the treatment of neuroendocrine tumors

1 reference

12 December 2020

1 reference

12 December 2020

Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation

1 reference

12 December 2020

Cyclic ectopic Cushing's syndrome and somatostatin analogue treatment.

1 reference

12 December 2020

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

12 December 2020

Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors

1 reference

12 December 2020

VIPomas: an update in diagnosis and management in a series of 11 patients.

1 reference

12 December 2020

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

1 reference

12 December 2020

1 reference

12 December 2020

An update on gastroenteropancreatic neuroendocrine tumors

1 reference

12 December 2020

Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors

1 reference

12 December 2020

10.1007/S40265-015-0397-7

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1042676274

0 references

1 reference